ProQR to Participate in Upcoming Investor Conferences
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced participation in several upcoming investor conferences aimed at discussing its focus on RNA medicines for inherited retinal diseases. Key events include the Citi's 15th Annual BioPharma Virtual Conference on September 10, the H.C. Wainwright 22nd Annual Conference on September 15, the Cantor Virtual Global Healthcare Conference on September 16, and the Chardan Virtual 4th Annual Genetic Medicines Conference on October 6. Details of the presentations can be found on the company's website, with archived webcasts available post-presentation.
- None.
- None.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for inherited retinal diseases (IRDs), today announced that Company management will participate in the following upcoming investor conferences:
- Citi's 15th Annual BioPharma Virtual Conference
Thursday, September 10, 9:50-10:35 AM EST – Ophthalmology Panel - H.C. Wainwright 22nd Annual Global Investment Conference
Tuesday, September 15, 1:30-1:50 PM EST – Fireside Chat - Cantor Virtual Global Healthcare Conference
Wednesday, September 16, 2:00-2:30 PM EST – Fireside Chat - Chardan Virtual 4th Annual Genetic Medicines Conference
Tuesday, October 6, 4:15-4:45 PM EST – Fireside Chat
Presentation and webcast details can be found under ‘Events’ in the ‘Investors & Media’ section of the Company’s website (www.proqr.com). Archived webcasts will be available for approximately 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in these conferences. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 535 7743
hans@lifesciadvisors.com
Media Contact:
Sara Zelkovic
LifeSci Public Relations
T: +1 646 876 4933
sara@lifescipublicrelations.com
FAQ
What are the upcoming investor conferences for ProQR (PRQR) in September 2020?
When is the Chardan Virtual 4th Annual Genetic Medicines Conference for ProQR (PRQR)?
Where can I find details about ProQR's (PRQR) presentations?
How long will ProQR (PRQR) archived webcasts be available after the presentations?
What does ProQR (PRQR) focus on in its research and development?
